Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosneft reported for 3 months of 2023 by IFRS

5/31/23 ROSN

HP reported for 6 months of fiscal year 2023

5/31/23 HPQ

Novatek wants to build an LNG plant in the Murmansk region with a capacity of 20.4 million tons

5/31/23 NVTK

Shareholders of Korshynov Mining Plant approved dividends for 2023

5/30/23 KOGK

Rostelekom gained control in manufacturer of telecom equipment Bulat

5/30/23 RTKM

Veon reached the final stage of selling Russian assets

5/30/23 VEON

Shareholders of Territorial Generating Company № 14 approved dividends for 2022

5/30/23 TGKN

Board of Directors of Svetofor Group recommended that dividends be paid for 2022

5/30/23 SVET

Polymetal shareholders approve re-domiciliation to Kazakhstan

5/30/23 POLY

RusHydro reported for 3 months of 2023 by IFRS

5/30/23 HYDR